6.3 Multigene Genomic Assays & Recurrence Risk Stratification

The clinical management of early-stage breast cancer has been transformed by multigene expression profiling. In hormone receptor-positive, HER2-negative breast cancer—which represents approximately 70% of all breast malignancies—traditional clinicopathologic parameters such as patient age, tumor diameter, and histologic grade are insufficient to accurately differentiate indolent tumors from micrometastatic disease. Multigene genomic assays quantify messenger RNA (mRNA) expression of tumor gene panels to provide two essential clinical insights: a prognostic estimate of the likelihood of distant recurrence following standard endocrine therapy, and a predictive assessment of the absolute benefit gained by adding cytotoxic chemotherapy to adjuvant endocrine treatment.

The Oncotype DX Breast Recurrence Score (21-Gene Assay)

The Oncotype DX assay is the most widely utilized and clinically validated genomic assay in early-stage breast cancer. Performed via quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) on formalin-fixed paraffin-embedded (FFPE) primary tumor tissue, the assay evaluates a specific panel of 21 genes:

• 16 Cancer-Related Genes: Grouped into functional biologic modules including the proliferation module (Ki-67, STK15, Survivin, CCNB1, MYBL2), the estrogen receptor module (ER, PGR, BCL2, SCUBE2), the HER2 module (ERBB2, GRB7), the invasion module (Stromelysin 3, Cathepsin L2), and three individually weighted genes (GSTM1, BAG1, CD68).
• 5 Reference (Housekeeping) Genes: ACTB, GAPDH, RPLP0, GUS, and TFRC, used to normalize expression levels across specimens.

The algorithmic output is a continuous Recurrence Score (RS) ranging from 0 to 100, where higher scores correlate with increased proliferation, lower hormonal dependence, and elevated risk of distant metastasis.

The Landmark TAILORx Trial (Node-Negative Disease)

The TAILORx trial evaluated 10,273 women with hormone receptor-positive, HER2-negative, axillary node-negative breast cancer to define optimal chemotherapy use across specific Recurrence Score categories:

• RS 0 to 10 (Low Risk): Patients treated with endocrine therapy alone had a 9-year distant recurrence rate of about 3%. Adjuvant cytotoxic chemotherapy provides no measurable benefit.
• RS 11 to 25 (Intermediate Risk): Patients were randomized to receive either endocrine therapy alone or chemoendocrine therapy. In the primary analysis of the overall trial population, endocrine therapy alone was non-inferior to chemoendocrine therapy (9-year disease-free survival 83.3% vs. 84.3%), confirming that the majority of patients with intermediate scores can safely avoid chemotherapy.
  • The Age-Interaction Caveat: In pre-planned exploratory subgroup analyses, women aged 50 years or younger with an RS of 16 to 25 experienced a statistically significant reduction in distant recurrence with chemotherapy. Specifically, the absolute chemotherapy benefit was 1.6% for RS 16 to 20, and 6.5% for RS 21 to 25. Much of this observed benefit in younger women is hypothesized to stem from chemotherapy-induced amenorrhea and ovarian function suppression rather than direct cytotoxic effects on tumor cells.
• RS 26 to 100 (High Risk): These patients were assigned chemoendocrine therapy rather than randomized; their 9-year distant recurrence rate was about 13% even with chemotherapy, and earlier NSABP B-20 data showed a large absolute chemotherapy benefit for high scores, so chemotherapy is recommended.

The RxPONDER Trial (1 to 3 Positive Lymph Nodes)

The SWOG S1007 RxPONDER trial investigated whether postmenopausal and premenopausal patients with hormone receptor-positive, HER2-negative breast cancer and 1 to 3 positive axillary lymph nodes (pN1) and an RS of 0 to 25 could safely omit chemotherapy:

• Postmenopausal Women: There was no statistically significant difference in 5-year invasive disease-free survival (IDFS) between endocrine therapy alone (91.9%) and chemoendocrine therapy (91.3%). Postmenopausal patients with 1 to 3 positive nodes and an RS of 0 to 25 can safely omit adjuvant chemotherapy.
• Premenopausal Women: Premenopausal women had a statistically significant improvement of about 5 percentage points in 5-year IDFS (93.9% with chemotherapy vs. 89.0% without in the 2021 NEJM report), with benefit seen whether the RS was 0 to 13 or 14 to 25. Consequently, premenopausal node-positive patients continue to warrant adjuvant chemotherapy followed by endocrine therapy.

Alternative Multigene Genomic Profiling Assays

Several other multigene platforms are recognized by clinical guidelines to assist in risk stratification and adjuvant decision-making.

The MammaPrint Assay & the MINDACT Trial

The 70-gene MammaPrint signature stratifies tumors into Genomic Low Risk or Genomic High Risk. The prospective Phase III MINDACT trial examined patients with discordant clinical and genomic risks (determined by Adjuvant! Online clinicopathologic criteria versus MammaPrint). Among patients classified as Clinically High Risk but Genomically Low Risk (C-High / G-Low), those who received endocrine therapy alone without chemotherapy achieved a 5-year distant metastasis-free survival of 94.7%, supporting chemotherapy omission for about 46% of clinically high-risk patients. Longer follow-up showed a small benefit from chemotherapy (about 5 percentage points at 8 years) in women 50 or younger in this group, a pattern similar to the TAILORx age effect.

The Breast Cancer Index (BCI) and Extended Endocrine Therapy

While assays like Oncotype DX and MammaPrint guide upfront chemotherapy decisions, the Breast Cancer Index (BCI) addresses a different clinical question: Which patients benefit from extending adjuvant endocrine therapy from 5 years to 10 years? BCI combines two independent biomarkers: the Molecular Grade Index (assessing proliferation) and the two-gene expression ratio of HOXB13 to IL17BR (H/I ratio, assessing estrogen signaling). Patients reported as "BCI High" demonstrate a statistically significant reduction in late distant recurrences with extended endocrine therapy (years 5 to 10), whereas patients reported as "BCI Low" experience no significant benefit and can avoid the toxicities of prolonged treatment.

Nursing Considerations in Genomic Risk Communication

Breast care nurses play an indispensable role in patient advocacy, education, and shared decision-making throughout genomic testing:

• Managing Waiting Anxiety: Genomic assay results typically require 10 to 14 days for central laboratory processing. Nurses provide crucial emotional support during this waiting period, setting realistic timelines and preparing patients for nuanced risk discussions.
• Translating Risk into Patient-Centric Terms: Patients often misinterpret an Oncotype DX Recurrence Score as a "passing or failing grade." Nurses clarify that the score reflects an individualized estimate of distant recurrence risk and guides whether chemotherapy adds meaningful benefit beyond hormonal pills.
• Navigating Age-Dependent Nuances: For young women (aged 50 or younger) with Recurrence Scores of 16 to 25, nurses explain that the modest benefit observed with chemotherapy may be attributable to ovarian suppression. This allows multidisciplinary teams to explore alternative strategies, such as ovarian function suppression (OFS with GnRH agonists) combined with an aromatase inhibitor, as evaluated in the SOFT and TEXT trials.
• Supporting Extended Therapy Decisions: For patients completing 5 years of adjuvant endocrine therapy who struggle with severe arthralgias, bone loss, or menopausal vasomotor symptoms, nurses can advocate for BCI testing to determine whether continuing treatment for another 5 years offers proven clinical value.